tiprankstipranks
Trending News
More News >
Estrella Immunopharma (ESLA)
NASDAQ:ESLA
US Market

Estrella Immunopharma (ESLA) Stock Statistics & Valuation Metrics

Compare
36 Followers

Total Valuation

Estrella Immunopharma has a market cap or net worth of $60.05M. The enterprise value is $41.04M.
Market Cap$60.05M
Enterprise Value$41.04M

Share Statistics

Estrella Immunopharma has 37,765,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,765,590
Owned by Insiders
Owned by Institutions0.13%

Financial Efficiency

Estrella Immunopharma’s return on equity (ROE) is -61.56 and return on invested capital (ROIC) is -6155.69%.
Return on Equity (ROE)-61.56
Return on Assets (ROA)-2.82
Return on Invested Capital (ROIC)-6155.69%
Return on Capital Employed (ROCE)-61.55
Revenue Per Employee0.00
Profits Per Employee-2.95M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Estrella Immunopharma is ―. Estrella Immunopharma’s PEG ratio is -0.26.
PE Ratio
PS Ratio0.00
PB Ratio306.25
Price to Fair Value306.25
Price to FCF-5.76
Price to Operating Cash Flow-25.03
PEG Ratio-0.26

Income Statement

In the last 12 months, Estrella Immunopharma had revenue of 0.00 and earned -8.85M in profits. Earnings per share was -0.25.
Revenue0.00
Gross Profit0.00
Operating Income-8.85M
Pretax Income-8.85M
Net Income-8.85M
EBITDA-8.85M
Earnings Per Share (EPS)-0.25

Cash Flow

In the last 12 months, operating cash flow was -2.50M and capital expenditures -4.00, giving a free cash flow of -2.50M billion.
Operating Cash Flow-2.50M
Free Cash Flow-2.50M
Free Cash Flow per Share-0.07

Dividends & Yields

Estrella Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.49
52-Week Price Change35.90%
50-Day Moving Average2.03
200-Day Moving Average1.25
Relative Strength Index (RSI)41.15
Average Volume (3m)165.74K

Important Dates

Estrella Immunopharma upcoming earnings date is ―, ―.
Last Earnings Date
Next Earnings Date
Ex-Dividend Date

Financial Position

Estrella Immunopharma as a current ratio of 0.55, with Debt / Equity ratio of -0.04%
Current Ratio0.55
Quick Ratio0.55
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Estrella Immunopharma has paid 1.69K in taxes.
Income Tax1.69K
Effective Tax Rate>-0.01

Enterprise Valuation

Estrella Immunopharma EV to EBITDA ratio is -4.87, with an EV/FCF ratio of -5.64.
EV to Sales0.00
EV to EBITDA-4.87
EV to Free Cash Flow-5.64
EV to Operating Cash Flow-5.64

Balance Sheet

Estrella Immunopharma has $1.63M in cash and marketable securities with $4.00K in debt, giving a net cash position of $1.62M billion.
Cash & Marketable Securities$1.63M
Total Debt$4.00K
Net Cash$1.62M
Net Cash Per Share$0.04
Tangible Book Value Per Share<$0.01

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Estrella Immunopharma is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target
Price Target Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score5
AI Score